First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial
Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer’s disease
Enrolment in XanaCIDD phase 2a tr… อ่านเพิ่ม